Innate Pharma began a Phase 1 study (NCT06781983) of IPH4502 in solid tumors. The study has two parts: dose escalation and dose optimization part, enrolling approximately 105 patients

IPH4502 targets Nectin-4 in solid tumors. Tumors targeted include urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers but not limited to it